Vera Therapeutics to Host ASN Kidney Week Investor Webcast and Third Quarter 2026 Financial Results Conference Webcast
Key Highlights
- ➤October 22 webcast to discuss ORIGIN 3 final efficacy results for TRUTAKNA in IgAN
- ➤ORIGIN 3 results featured in ASN Kidney Week 2026 opening plenary late-breaking presentation
- ➤November 5 webcast scheduled to discuss Q3 2026 financial results and business updates
- ➤TRUTAKNA approved under accelerated approval to reduce proteinuria in adults with IgAN
Expert Statements
Jonathan Barratt, Mayer Professor of Renal Medicine at the University of Leicester
“Joining the Company’s management team will be Jonathan Barratt, PhD, FRCP, Mayer Professor of Renal Medicine at the University of Leicester.”
* Investor webcast at 4:30 p.m. ET on October 22 to discuss ORIGIN 3 final efficacy results for TRUTAKNA™ (atacicept-vymj) featured in a late-breaking oral presentation during the opening plenary session of ASN Kidney Week 2026 * Q3 2026 financial results investor webcast scheduled at 4:30 p.m. ET on November 5 BRISBANE, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that it will host two upcoming investor webcasts to discuss ORIGIN 3 final efficacy results as presented at the American Society of Nephrology (ASN) Kidney Week 2026 and its third quarter 2026 financial results and business updates.
The Company’s management team will host a live investor webcast at 4:30 p.m. ET on Thursday, October 22, 2026, to discuss the final efficacy analysis from the ORIGIN 3 clinical trial of TRUTAKNA in IgA nephropathy (IgAN), which will be featured in a late-breaking oral presentation during the opening plenary session of ASN Kidney Week 2026.
Get started
Create a free account to read the full story.